American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 726-729 , May 2009

Kidney Damage in Metabolic Syndrome: Nip It in the Bud

  • Eberhard Ritz, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Eberhard Ritz, MD, Nierenzentrum, Im Neuenheimer Feld 162, Heidelberg, Germany D 60100

References 

  1. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–1209
  2. Zimmet P, Alberti G, Kaufman F, et al. The metabolic syndrome in children and adolescents. Lancet. 2007;369:2059–2061
  3. Alexander MP, Patel TV, Farag YMK, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: A cross-sectional study. Am J Kidney Dis. 2009;53:751–759
  4. Hitzenberger K. R-QM (Ein Beitrag zum Stoffwechsel bei der vaskulären Hypertonie). Wiener Arch Innere Med. 1921;2:189
  5. Reaven GM. Banting lecture 1988 (Role of insulin resistance in human disease). Diabetes. 1988;37:1595–1607
  6. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333–1445
  7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  8. Reaven GM. The metabolic syndrome: Requiescat in pace. Clin Chem. 2005;51:931–938
  9. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–2304
  10. Grundy SM. Point: The metabolic syndrome still lives. Clin Chem. 2005;51:1352–1354
  11. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28
  12. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–1876
  13. Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003;12:195–200
  14. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–1217
  15. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int. 1996;49:1774–1777
  16. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008;294:F685–F696
  17. Rocchini AP, Katch V, Kveselis D, et al. Insulin and renal sodium retention in obese adolescents. Hypertension. 1989;14:367–374
  18. Landsberg L. Insulin-mediated sympathetic stimulation: Role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001;19:523–528
  19. Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol. 2007;27:529–537
  20. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension. 2007;49:355–364
  21. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358–363
  22. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–14216
  23. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: Is increased aldosterone in metabolic syndrome patients an additional risk factor?. Hypertension. 2008;51:1252–1258
  24. Bonnet F, Marre M, Halimi JM, et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: The DESIR Study. J Hypertens. 2006;24:1157–1163
  25. Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003;41:733–741
  26. Altiparmak MR, Pamuk ON, Pamuk GE, Apaydin S, Ozbay G. Diffuse diabetic glomerulosclerosis in a patient with impaired glucose tolerance: Report on a patient who later develops diabetes mellitus. Neth J Med. 2002;60:260–262
  27. Souraty P, Nast CC, Mehrota R, Barba L, Martina J, Adler SG. Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nat Clin Pract Nephrol. 2009;4:639–642
  28. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: A complication of massive obesity. Ann Intern Med. 1974;81:440–447
  29. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int. 2001;59:1498–1509
  30. Alexander JW, Goodman HR, Hawver LR, Cardi MA. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis. 2009;5:237–241
  31. Agrawal V, Khan I, Rai B, et al. The effect of weight loss after bariatric surgery on albuminuria. Clin Nephrol. 2008;70:194–202
  32. Fowler SM, Kon V, Ma L, Richards WO, Fogo AB, Hunley TE. Obesity-related focal and segmental glomerulosclerosis: Normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol. 2009;24:851–855
  33. Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006;48:772–779
  34. Chen HM, Li SJ, Chen HP, Wang QW, Li LS, Liu ZH. Obesity-related glomerulopathy in China: A case series of 90 patients. Am J Kidney Dis. 2008;52:58–65
  35. Rea DJ, Heimbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 2006;70:1636–1641
  36. Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947–955
  37. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438–3446

PII: S0272-6386(09)00396-5

doi: 10.1053/j.ajkd.2009.02.001

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 726-729 , May 2009

Article Tools